Perkins Capital Management Inc. Has $2.33 Million Stock Holdings in MDxHealth SA (NASDAQ:MDXH)

Perkins Capital Management Inc. grew its position in MDxHealth SA (NASDAQ:MDXH) by 31.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 983,475 shares of the company’s stock after purchasing an additional 236,100 shares during the period. MDxHealth comprises about 2.1% of Perkins Capital Management Inc.’s portfolio, making the stock its 15th largest position. Perkins Capital Management Inc. owned approximately 2.08% of MDxHealth worth $2,331,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Maven Securities LTD acquired a new stake in MDxHealth in the third quarter worth $208,000. OneDigital Investment Advisors LLC increased its position in shares of MDxHealth by 15.3% during the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after acquiring an additional 7,656 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after acquiring an additional 10,000 shares in the last quarter.

MDxHealth Stock Up 0.6 %

Shares of MDXH stock opened at $1.60 on Monday. The company has a market capitalization of $75.66 million, a price-to-earnings ratio of -1.05 and a beta of 1.37. MDxHealth SA has a 12-month low of $1.35 and a 12-month high of $3.50. The firm has a fifty day moving average of $1.80 and a 200-day moving average of $2.03. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. As a group, equities research analysts predict that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.